Abstracts tagged "Disease Activity"

Abstract Number: 1029 • 2013 ACR/ARHP Annual Meeting
Quality Of Life In Rheumatoid Arthritis: Cross-National Comparison Study Between US and South Korea
Yoon-Kyoung Sung^1,2, Kazuki Yoshida^2,3, Femke H.M. Prince^2,4, Michelle A. Frits², Jung-Yoon Choe⁵, Won Tae Chung⁶, Jisoo Lee⁷, Eun-Mi Koh⁸, Dae-Hyun Yoo⁹, Simon M. Helfgott², Nancy A. Shadick¹⁰, Michael E. Weinblatt¹¹, Sang-Cheol Bae¹ and Daniel H. Solomon², ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, ⁴Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ⁵Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ⁷Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ⁸Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁰Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ¹¹Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Quality of life (QOL) is a well-established outcome for rheumatoid arthritis (RA) trials. To perform trials with QOL as an outcome involving many countries,…
Abstract Number: 380 • 2013 ACR/ARHP Annual Meeting
Active Rheumatoid Arthritis Is An Independent Risk Factor Of Chronic Kidney Disease
Ryosuke Hanaoka^1,2, Kazuhiro Kurasawa³, Ayae Tanaka⁴ and Harutsugu Okada⁵, ¹Department of Rheumatology, Kamitsuga General Hospital, Kanuma, Japan, ²Department of Rheumatology, Kamitsuga General Hospital, Kanuma, Tochigi, Japan, ³Clinical Immunology, Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi-ken, Japan, ⁴Clinical Immunology, Dokkyo Medical University, Mibu, Tochigi, Japan, ⁵Clinical Immunology, Dokkyo Medical University, Mibu-machi, Tochigi-ken, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that affects not only joints but also many organs. RA causes vascular damages to contribute to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].